Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04613596 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
A Phase 2 study of Metastatic Non Small Cell Lung Cancer and Advanced Non-Small-Cell Lung Cancer, sponsored by Mirati Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 806
- Enrollment target
- 20
- Study locations
NCT04613596 is a Phase 2 study of Metastatic Non Small Cell Lung Cancer and Advanced Non-Small-Cell Lung Cancer that is actively recruiting participants, run by Mirati Therapeutics. The registered enrollment target is 806 participants, above the 367-participant average among 30 other Metastatic Non Small Cell Lung Cancer trials with a reported enrollment target (120% higher). The trial reports 20 study locations across 3 states.
The verdict
NCT04613596, a Phase 2 study of Metastatic Non Small Cell Lung Cancer and Advanced Non-Small-Cell Lung Cancer, is actively recruiting participants, sponsored by Mirati Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 806 participants
- Enrollment target
- 20
- Study locations
Study Summary
The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates for first-line treatment. The Phase 3 portion of the study compares the efficacy of adagrasib in combination with pembrolizumab versus pembrolizumab in patients with unresectable, locally advanced or metastatic squamous or nonsquamous NSCLC with KRAS G12C mutation and PD-L1 TPS \>=50% and who are candidates for first line treatment.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Adagrasib
Study Locations (20)
California
- Providence - Saint Joseph Home Health - Anaheim - Anaheim
- The Oncology Institute of Hope and Innovation - Corporate Office - Cerritos
- Local Institution - 007-777 - Fountain Valley
- Local Institution - 007-778 - Laguna Hills
- Local Institution - 007-898-B - Long Beach
- MemorialCare - Long Beach Medical Center - Long Beach
- TRIO - Cancer & Blood Specialty Clinic - Los Alamitos - Los Alamitos
- Local Institution - 007-579 - Los Angeles
- Local Institution - Unk045 - Rancho Mirage
- San Francisco Veterans Affairs Medical Center - San Francisco
- UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco
Arizona
- Local Institution - 007-556-A - Goodyear
- USOR - Arizona Oncology - Prescott Valley - Prescott Valley
- Local Institution - 007-568-A - Safford
- Local Institution - 007-568-B - Safford
- Local Institution - 007-568-C - Safford
- Local Institution - 007-568-D - Safford
- Local Institution - 007-568-E - Safford
- Arizona Clinical Research Center - Tucson
Arkansas
- Highlands Oncology Group - Springdale - Springdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 806 participants |
| Start Date | 2020-12-02 |
| Est. Completion | 2029-10-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04613596
The ClinicalTrials.gov registry entry for NCT04613596 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 806 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 367-participant average among 30 other Metastatic Non Small Cell Lung Cancer trials with a reported enrollment target (120% higher). The listed sponsor is Mirati Therapeutics, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Metastatic Non Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT04613596 reports 20 study locations spanning 3 distinct geographic areas - top geographies include California, Arizona, Arkansas.
Frequently Asked Questions
What is clinical trial NCT04613596 about?
NCT04613596 is a clinical study titled "Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7". The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates for first-line treatment. The Phase 3 portion of the study com...
What is the current status of trial NCT04613596?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 806 participants. The study started on 2020-12-02. Estimated completion is 2029-10-31.
What conditions does trial NCT04613596 study?
This clinical trial studies the following conditions: Metastatic Non Small Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer.
What interventions are being tested in trial NCT04613596?
The interventions under investigation include: Pembrolizumab (DRUG), Adagrasib (DRUG).
Who is sponsoring clinical trial NCT04613596?
This trial is sponsored by Mirati Therapeutics, which has 49 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04613596 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Non Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
RECRUITING · Phase 2
-
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
RECRUITING · Phase 2
-
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
ACTIVE NOT RECRUITING · Phase 2
-
Plasma-Adapted First-Line Pembro In NSCLC
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Metastatic Non Small Cell Lung Cancer
All registered trials for this condition
Advanced Non-Small-Cell Lung Cancer
All registered trials for this condition
Arizona
All trials with a study site in Arizona
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.